Immunoglobulins Market to 2019 – Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer’s Disease...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 11
2 Immunoglobulins Market to 2019 – Introduction 12
2.1 Overview 12
3 Immunoglobulins Market to 2019 – Market Overview 13
3.1 Revenue 13
3.2 Annual Cost of Therapy 14
3.3 Immunoglobulins Market Drivers and Restraints 15
3.3.1 Market Drivers 15
3.3.2 Restraints 16
4 Immunoglobulins Market to 2019 – Geographical Landscape 17
4.1 US 17
4.1.1 Revenue 17
4.1.2 Annual Cost of Therapy 19
4.2 Top Five European Countries 20
4.2.1 Revenue 20
4.2.2 Annual Cost of Therapy 22
4.3 Japan 23
4.3.1 Revenue 23
4.3.2 Annual Cost of Therapy 24
5 Immunoglobulins Market to 2019 – Therapeutic Landscape 25
5.1 Main Therapeutic Indications 25
5.1.1 Indicated Conditions for Intravenous Immunoglobulin Usage – US 25
5.1.2 Indications for Intravenous Immunoglobulin Usage – Europe 25
5.1.3 Guidelines for Intravenous Immunoglobulin Usage – UK 26
5.1.4 Indications for Intravenous Immunoglobulin Usage – Japan 26
5.2 Revenue Share for the Major Therapeutic Indications 27
5.3 Primary Immunodeficiency Market 28
5.3.1 Introduction 28
5.3.2 Revenue 29
5.3.3 Annual Cost of Therapy 31
5.3.4 Epidemiology 33
5.3.5 Current Use 35
5.3.6 Geographical Segmentation 36
5.4 Guillain-Barré Syndrome Market 37
5.4.1 Introduction 37
5.4.2 Revenue 38
5.4.3 Annual Cost of Therapy 39
5.4.4 Epidemiology 40
5.4.5 Current Use for Therapies 41
5.4.6 Geographical Segmentation 42
5.5 Chronic Lymphocytic Leukemia Market 44
5.5.1 Introduction 44
5.5.2 Revenue 45
5.5.3 Annual Cost of Therapy 46
5.5.4 Epidemiology 47
5.5.5 Current Use 48
5.5.6 Geographical Segmentation 49
5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market 51
5.6.1 Introduction 51
5.6.2 Revenue 52
5.6.3 Annual Cost of Therapy 53
5.6.4 Epidemiology 54
5.6.5 Current Use 55
5.6.6 Geographical Segmentation 56
5.7 Myasthenia Gravis Market 58
5.7.1 Introduction 58
5.7.2 Revenue 59
5.7.3 Annual Cost of Therapy 60
5.7.4 Epidemiology 61
5.7.5 Current Use 62
5.7.6 Geographical Segmentation 63
5.8 Multifocal Motor Neuropathy Market 65
5.8.1 Introduction 65
5.8.2 Revenue 66
5.8.3 Annual Cost of Therapy 67
5.8.4 Epidemiology 68
5.8.5 Current Use 69
5.8.6 Geographical Segmentation 70
5.9 Idiopathic Thrombocytopenic Purpura 72
5.9.1 Introduction 72
5.9.2 Revenue 73
5.9.3 Annual Cost of Therapy 74
5.9.4 Epidemiology 75
5.9.5 Current Use 76
5.9.6 Geographical Segmentation 77
6 Immunoglobulins Market to 2019 – Profiles of Marketed Products 79
6.1 Overview 79
6.2 Privigen 81
6.2.1 Overview 81
6.2.2 Approved Indications 81
6.2.3 Safety 81
6.2.4 Efficacy 82
6.3 Gammagard S/D 83
6.3.1 Overview 83
6.3.2 Approved Indications 83
6.3.3 Safety 83
6.3.4 Efficacy 84
6.4 Gammagard Liquid 85
6.4.1 Overview 85
6.4.2 Approved Indications 85
6.4.3 Safety 85
6.4.4 Efficacy 86
6.5 Octagam 5% 87
6.5.1 Overview 87
6.5.2 Approved Indications 87
6.5.3 Safety 87
6.5.4 Efficacy 88
6.6 Flebogamma 10% DIF 88
6.6.1 Overview 88
6.6.2 Approved Indications 88
6.6.3 Safety 88
6.6.4 Efficacy 88
6.7 Gamunex-C 89
6.7.1 Overview 89
6.7.2 Approved Indications 89
6.7.3 Safety 89
6.7.4 Efficacy 90
6.8 Gammaplex 91
6.8.1 Overview 91
6.8.2 Approved Indications 91
6.8.3 Safety 91
6.8.4 Efficacy 92
6.9 HyQvia 93
6.9.1 Overview 93
6.9.2 Approved Indications 93
6.9.3 Safety 93
6.9.4 Efficacy 93
6.10 Bivigam 94
6.10.1 Overview 94
6.10.2 Approved Indications 94
6.10.3 Safety 94
6.10.4 Efficacy 94
7 Immunoglobulins Market to 2019 – Pipeline Analysis 95
7.1 Research and Development Pipeline 95
7.2 Major Pipeline Product Profiles 97
7.2.1 IVIG3I Grifols 10% 97
7.2.2 RI-002 (IVIG) 98
8 Immunoglobulins Market to 2019 – Competitive Landscape 99
8.1 Baxter International Inc. 99
8.1.1 Business Description 99
8.1.2 Recent Developments 100
8.2 Biotest Pharmaceuticals 101
8.2.1 Business Description 101
8.2.2 Recent Developments 101
8.3 Bio Products Laboratory Ltd. 102
8.3.1 Business Description 102
8.3.2 Recent Developments 102
8.4 CSL Behring Limited 103
8.4.1 Business Description 103
8.4.2 Recent Developments 103
8.5 Grifols S.A. 104
8.5.1 Business Description 104
8.5.2 Recent Developments 105
8.6 Octapharma AG 106
8.6.1 Business Description 106
8.6.2 Recent Developments 106
9 Immunoglobulins Market to 2019 – M&A and Licensing Deals Landscape 107
9.1 M&A Deals 107
9.1.1 Grifols Buys 60% of Progenika Biopharma 107
9.1.2 Grifols Acquires 40% of the Capital of Biotechnology Firm VCN Bioscience 107
9.1.3 Grifols Purchases Three Plasma Donation Centers in the US from Canada’s Cangene 107
9.1.4 Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro 107
9.2 R&D Licensing Agreements 108
9.2.1 Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib 108
9.2.2 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies 108
9.2.3 Baxter Announces 20 Year Partnership with Hemobras in Brazil 108
10 Immunoglobulins Market to 2019 – Asia-Pacific and China 109
10.1 India 109
10.1.1 Overview 109
10.1.2 Regulatory Landscape 109
10.1.3 National Institute for Biologicals 110
10.1.4 Marketed Products 110
10.1.5 Product Profiles 113
10.1.6 Company Profiling 114
10.2 China 118
10.2.1 Overview 118
10.2.2 Regulatory Information 118
10.2.3 Marketed Products 120
10.2.4 Company Profiling 121
10.3 Australia 123
10.3.1 Overview 123
10.3.2 Regulatory Landscape 125
10.3.3 Marketed Products 126
10.3.4 Product Profiles 127
10.3.5 Company Profiling 128
11 Global Immunoglobulins Market: Appendix 129
11.1 Market Definitions 129
11.2 Abbreviations 129
11.3 References 130
11.4 Research Methodology 132
11.4.1 Coverage 132
11.4.2 Secondary Research 133
11.4.3 Primary Research 133
11.4.4 Expert Panel Validation 133
11.5 Contact Us 134
11.6 Disclaimer 134